桂林三金(002275) - 桂林三金投资者关系管理信息(1)

Group 1: Financial Performance and Strategy - The company is focusing on cost control and optimizing personnel structure to reduce losses in its biopharmaceutical segment, which is currently facing challenges [1] - Sales expenses have been strictly controlled, with a trend towards more precise allocation, particularly favoring second and third-tier products [1] - The overall sales expenses and revenue are expected to remain stable without significant changes [1] Group 2: Product Development and Market Response - The company has not engaged in any applications for the national essential drug list adjustments, as this process is led by government departments [1] - The timing for the announcement of the new essential drug list is still undetermined by the authorities [1] - In Q1 2024, sales of key products like Sanjin Pian and Xigua Shuang were impacted by national policy changes, but measures taken have led to a gradual recovery in sales by Q2 [2] - The company aims to achieve its initial targets for the year by continuing to implement relevant policies and measures [2]